Interleukin 11 May improve thrombocytopenia associated with Imatinib mesylate therapy in chronic Myelogenous leukemia

Leukemia Research

Volumn 28, Issue 6, 2004, Pages 613-618

  Ault, Patricia ^a   Kantarjian, Hagop ^a   Welch, Mary Alma ^a   Giles, Francis ^a   Rios, Mary Beth ^a   Cortes, Jorge ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

CBC; Chronic myelogenous leukemia; Chronic myeloid leukemia; CML; Complete blood cell count; G CSG; Granulocyte colony stimulating factor (Filgrastin); IL 11; Imatinib; Interleukin 11; Oprelvekin; Thrombocytopenia; WBC; White blood cell count

Indexed keywords

ALPHA INTERFERON; CYTARABINE; CYTOKINE; IMATINIB; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11;

ADULT; ANAMNESIS; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; HUMAN; LABORATORY TEST; MALE; MORBIDITY; PERIPHERAL EDEMA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; INTERLEUKIN-11; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PIPERAZINES; PLATELET COUNT; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THROMBOCYTOPENIA; TIME FACTORS;

EID: 2142699732     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2003.11.003     Document Type: Article

References (18)

1. Kantarjian H., Sawyers C., Hochhaus A., Guilhot F., Schiffer C., Gambacorti-Passerini C., et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New England J Med. 346:2002;645-652
2. Kantarjian H.M., Talpaz M., O'Brien S., Smith T.L., Giles F.J., Faderl S., et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res. 8:2002;2177-2187
3. Kantarjian H.M., Cortes J.E., O'Brien S., Giles F., Garcia-Manero G., Faderl S., et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood. 101:2003;97-100
4. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 348:2003;994-1004
5. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England J Med. 344:2001;1031-1037
6. Du X., Williams D.A. Interleukin-11: review of molecular, cell biology, and clinical use. Blood. 89:1997;3897-3908
7. Saitoh M., Taguchi K., Momose K., Suga K., Yamazaki N., Ono C., et al. Recombinant human interleukin-11 improved carboplatin-induced thrombocytopenia without affecting antitumor activities in mice bearing Lewis lung carcinoma cells. Cancer Chemother Pharmacol. 49:2002;161-166
8. Tepler I., Elias L., Smith J.W. II, Hussein M., Rosen G., Chang A.Y., et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood. 87:1996;3607-3614
9. Gordon M.S., McCaskill-Stevens W.J., Battiato L.A., Loewy J., Loesch D., Breeden E., et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood. 87:1996;3615-3624
10. Isaacs C., Robert N.J., Bailey F.A., Schuster M.W., Overmoyer B., Graham M., et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol. 15:1997;3368-3377
11. Kurzrock R., Cortes J., Thomas D.A., Jeha S., Pilat S., Talpaz M. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol. 19:2001;4165-4172
12. Sneed TB, Kantarjian H, Talpaz M, O'Brien S, Rios MB, Wierda W, et al. In: Thomas D, Cortes J, editors. Significance of myelosuppression during the course of therapy with imatinib in patients with chronic myelogenous leukemia in chronic phase, Blood 100(2002)787a (Abstract #3110).
13. Kantarjian H.M., O'Brien S., Cortes J.E., Smith T.L., Rios M.B., Shan J., et al. Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 8:2002;2167-2176
14. Deininger M.W., O'Brien S.G., Ford J.M., Druker B.J. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 21:2003;1637-1647
15. Kurzrock R. rhIL-11 for the prevention of dose-limiting chemotherapy-induced thrombocytopenia. Oncology (Huntingt). 14:2000;9-11
16. Marin D, Marktel S, Foot N, Bua M, Olavarria E, Goldman JM, et al. G-CSF reverses cytopenia and may increase cytogenetic responses in patients with CML treated with imatinib mesylate, Blood 2002100:782a (Abstract #3091).
17. Ault P, Kantarjian H, O'Brien S, Garcia-Manero G, Rios MB, Cortes J, Use of darbopoietin alfa for the treatment of anemia occuring during imatinib therapy for CML: preliminary evidence of safety and efficacy, Proceedings ASCO. 200322:613 (Abstract #2467).
18. Mauro MJ, Blasdel C, O'Dwyer ME, Kurilik G, Capdeville R, Druker B, Erythropoietin for anemia during imatinib mesylate (STI571) therapy for CML: preliminary evidence of safety and efficacy. Proceedings ASCO. 200221:27a (Abstract #106).